Objective: To assess risk factors for injury among children and adolescents treated with stimulants for ADHD. Method: An analysis was performed of pharmacy and service claims data from 2000 focusing on children and adolescents ages 6 to 17 years who initiated stimulant therapy for ADHD. Bivariate and multivariate analyses were performed to examine associations of demographic and clinical characteristics with injury. Results: In a Cox proportional hazard model that controlled for background patient characteristics, patients ages 13 to 17 years, male gender, prescription of anxiolytic/hypnotic medications, and diagnosis of a mood disorder were each independently associated with increased risk of injury, whereas African American ancestry and other minority racial/ethnic ancestry were associated with lower risk. Youth with high stimulant medication possession ratios (MPR) had a nonsignificantly lower risk of injury as compared to those with a low stimulant MPR. Conclusion: These findings reveal several patient characteristics that may be associated with increased risk of injury among children and adolescents treated for ADHD. (J. of Att. Dis. 2008; 12(1) [64][65][66][67][68][69] 
In addition, there is emerging evidence that patients treated with extended-release OROS methylphenidate may be less likely to experience an accident or injury (Lage & Hwang, 2004) or use emergency or inpatient services than patients initiating treatment with immediate-release methylphenidate (Kemner & Lage, 2006) .
In the general population of young people, men tend to be at greater risk of injury than women (Soubhi, Raina, & Kohen, 2004) , and adolescents tend to be at greater risk than younger children (Scheidt et al., 1995) . Some epidemiological evidence further links pediatric depressive disorders to an increased risk of injury (Rowe et al., 2004) . Among adults, use of anxiolytics and hypnotics also has been correlated with an increased risk of injury (French, Campbell, Spehar, & Angaran, 2005; Stenbacka, Jansson, Leifman, & Romelsjo, 2002) . It is not known whether these and related factors contribute to the risk of injuries among youth who are receiving treatment for ADHD.
Inconsistent use of stimulants is common in the community care of children and adolescents with ADHD (Marcus, Wan, Kemner, & Olfson, 2005) . Given the short half-life of stimulant medications, this inconsistency may diminish treatment effects on known symptom and functional outcomes such as inattention, impulsivity, and hyperactivity (Charach, Ickowicz, & Schachar, 2004) . However, relationships between medication inconsistency and risk of injury remain unknown.
In the current report, we examine a large community cohort of children and adolescents undergoing long-term stimulant treatment for ADHD focusing on patient and service use characteristics associated with medical injuries during the episode of stimulant treatment. We further evaluate the association of stimulant continuity on risk of injury during this period.
Method Participants
Data were examined from the January 1, 2000, through December 31, 2003, statewide California Medicaid (Medi-Cal) claims files. We limited the sample to youth ages 6 to 17 years who received two or more outpatient claims for the treatment of ADHD (ICD-9-CM: 314). Patients who received treatment for a substance use disorder (ICD-9-CM: 291, 292, 303-305; Gau & Cheng, 2004) ; epilepsy (ICD-9-CM: 345; Sherrard, Tonge, & OzanneSmith, 2002) ; blindness or low vision (ICD-9-CM: 369; Vu, Keeffe, McCarty, & Taylor, 2005) ; hearing loss (ICD-9-CM: 389; Donmez & Gokkoca, 2003) ; mental retardation (ICD-9-CM: 317-319) or developmental delay (ICD-9-CM: 315; Sherrard et al., 2002) ; and conduct, oppositional defiant, or disruptive disorder not otherwise specified (ICD-9-CM: 312, 313.81; Piazza-Waggoner et al., 2005) were excluded because these conditions may independently increase the risk of injury.
The sample was further limited to patients who filled a prescription for methylphenidate or salts of amphetamine without a stimulant prescription in the preceding 120 days. To focus on a treated population, the sample also was limited to patients treated with at least 120 days separating the first day of the first filled stimulant prescription from the last day supplied of the last filled stimulant prescription. This period is referred to as the stimulant treatment episode. Patients also were required to be continuously eligible for Medicaid services throughout the stimulant treatment episode and the 120 days preceding it.
The Institutional Review Board of the University of Pennsylvania School of Social Policy & Practice approved all study procedures.
Stimulant Treatment
Stimulants included methylphenidate and salts of amphetamine. This included extended-release methylphenidate (Concerta, Metadate CD, Metadate ER, Ritalin LA, Ritalin SR, Methylin LA, Methylin ER, and methylphenidate ER) and salts of amphetamine (Adderall XR) as well as immediate-release methylphenidate (Ritalin, Methylin, Focalin, and methylphenidate) and salts of amphetamine (Adderall, amephetamine/dextroamphetamine, dextroamphetamine, methamphetamine, and Desoxyn).
A stimulant medication possession ratio (MPR) was calculated for each patient. The MPR was calculated by dividing the total number of days of stimulant medication supplied by the number of days in the stimulant treatment episode. On the basis of the MPR, stimulant adherence of each patient's treatment episode was classified as being low (< 0.3 MPR), medium (0.3-0.7 MPR), or high (> 0.7 MPR). The cut-points were selected on the basis of previous research with a child and adolescent Medicaid population indicating that the mean MPR for stimulants is approximately 0.7 (Sanchez, Crismon, Barner, Bettinger, & Wilson, 2005) . Each study patient contributed only one treatment episode to the analysis.
Injury
Following the classification developed by Spady, Saunders, Schopflocher, and Svenson (2004) , the first claim for an injury and poisoning (chap. 17) during the treatment episode was partitioned into 16 categories according to their ICD-9-CM diagnosis (see Table 1 ).
Other Patient Characteristics
Other patient characteristics included age in years, sex, race/ethnicity (White, Black, other), and use of an antipsychotic, antidepressant, mood stabilizer, and anxiolytic/ hypnotic medication during the stimulant treatment episode. Patients also were classified by occurrence of one or more claims for the treatment for a mood disorder (296, 300.4, 311) or an anxiety disorder (300.0, 300.2, 300.3, 308.3, 309.81) during the stimulant treatment episode.
Analytic Strategy
The distribution of injuries was first examined by injury category. No patient contributed more than one injury to this analysis. Patients were then compared with respect to their annualized risk of injury based on the daily injury rate during the episode of stimulant use. Comparisons were made with respect to background demographic characteristics, treatment with psychotropic medications, selected comorbid diagnoses, and stimulant MPR group. Using Cox proportional hazard models, adjusted and unadjusted Hazards Ratios (HRs) with associated p values were computed to examine the strength of independent associations between patient characteristics and the occurrence of first injury during the treatment episode.
Results
The most common injuries were superficial injuries and contusions (32.9%); open wounds (20.4%); dislocations, strains, and sprains (19.9%); and fractures of the upper limb (9.4%).
For the entire sample, the rate of injury per year was .230 (see Table 2 ). In the bivariate analyses, the risk of injury was significantly greater for adolescents (13-17 years) than children (6-12 years) and higher for White youth than Black youth or members of other ethnic/racial minority groups. The risk also was significantly greater for patients prescribed anxiolytics/hypnotics, mood stabilizers, or antidepressants than for patients not prescribed these medications and higher for patients with mood disorders than patients without a mood disorder (see Table 2 ).
In the adjusted Cox proportional hazard model (see Table 2 ), the rate of injury was significantly higher for adolescents (ages 13-17 years) than children (ages 6-12 years), men than women, and Caucasian patients compared with other racial/ethnic groups. In this model, the risk of injury also was significantly greater for patients who were treated with anxiolytics/hypnotics and who were treated for a comorbid mood disorder than those without these characteristics. As compared with low stimulant MPR, high stimulant MPR was associated with a nonsignificant trend toward a decrease in risk of injury (HR = .89, p = .07). 
Discussion
In this group of children and adolescents treated for ADHD, patients ages 13 to 17 years, male gender, prescription of anxiolytic/hypnotic medications, and diagnosis of a mood disorder were associated with increased risk of injury, whereas African American ancestry and other minority racial/ethnic ancestry were associated with lower risk. There was also a statistically nonsignificant trend toward an inverse relationship between stimulant adherence and risk of injury. In this study, the most common injuries, which included superficial injuries and contusions; open wounds; and dislocations, strains, and sprains, were likely to have been relatively minor rather than severe or morbid.
The pattern of injuries across patient age (Scheidt et al., 1995) and gender (Soubhi et al., 2004 ) groups parallels findings from epidemiologic studies of children and adolescents in the general population. The higher percentage of treated injuries among boys than girls is presumably related to boys engaging in more risk-taking behaviors than girls. It is also possible that gender differences in the clinical presentation of ADHD contribute to the gender difference in proportion of injuries. In clinic samples, boys with ADHD tend to have more hyperactivity, aggression with peers, and externalizing behaviors than girls with ADHD (Gaub & Carlson, 1997) . However, inattention provides another plausible pathway to increased risk of injury.
It remains unclear why a higher proportion of White than non-White youth treated for ADHD receive treatment for injuries. Although some evidence indicates that minority children, especially Black children, have a significantly higher percentage of serious injuries than White children (Hayes & Groner, 2005) , other research suggests the reverse (Scheidt et al., 1995) . Moreover, the overall risk of injury tends to be inversely related to socioeconomic status (Brown, Chishti, & Stone, 2005) Source: Data from Medi-Cal (2000 . Note: CI = confidence interval; MPR = medication possession ratio; HR = Hazards Ratio. The race variable is missing for 46 patients. and little is known about the effects of race on risk of youth injury within low-income populations such as those in the Medicaid program. One small study reported that Black children with ADHD have less psychiatric comorbidity and dysfunction than ostensibly similar Caucasian children (Samuel, Biederman, & Faraone, 1998) , which may place the African American youth at lower risk of injury. The use of benzodiazepines (French et al., 2005) and other sedative/hypnotics (Stenbacka et al., 2002) has been associated with an increased risk of injuries in adults. In epidemiological research, children and adolescents with depressive disorders also have been found to be at increased risk of several types of unintentional injuries (Rowe et al., 2004) . The present findings extend these observations to young people treated for ADHD.
The overall rate of injury in this sample (23.0% per year) falls in the range of previous reports of children and adolescents in the general population. Using a variety of methods, it has been estimated that between 20% and 30% of young people are injured during the course of 1 year (Gallagher, Finison, Guyer, & Goodenough, 1984; Harel et al., 1994; Scheidt et al., 1995; Spady et al., 2004) . According to the 1988 National Health Interview Survey, for example, an estimated 27.0% of adolescents 14 to 17 years of age sustain an injury each year (Scheidt et al., 1995) . This is only slightly below the 30.1% figure reported in the current sample of adolescents ages 13 to 19 years who have been treated with stimulants for ADHD. Although methodological differences between the studies prevent direct comparisons, the current findings suggest that young people treated for ADHD are at most only slightly more at risk of injury than young people in the general population. In this respect, the current findings contrast with an earlier report from a representative community sample that children and adolescents who meet criteria for ADHD are at a significantly greater risk of injury than children without psychiatric disorders (Rowe et al., 2004) .
The current study has several limitations. First, stimulants and other psychotropic treatments were assessed with claims records that may inaccurately measure medication utilization and adherence. Although pharmacy claims have been found to measure psychotropic medication utilization with reasonable accuracy (Kirking, Ammann, & Harrington, 1996) , pill counts or electronic monitoring might have yielded more accurate information. Because some children and adolescents receive stimulant therapy only during selected periods of the week (Martins et al., 2004) , stimulant MPR may vary as a function of planned episodic use or inadvertent stimulant nonadherence. Second, no information was available concerning the physical safety of the living environment, parental supervision and monitoring, or other factors that may influence risk of injury. Some of these factors may have confounded the association between stimulant adherence and injury. Third, the analyses capture a wide range of injuries that receive medical attention. More detailed analytic methods and larger samples are required to evaluate associations between stimulant treatment and each of type of injury. Fourth, because the study is limited to Medicaid beneficiaries, the results may not be safely generalized to privately insured youth. The risk of injury within this predominantly low-income Medicaid sample may differ from that within a more affluent, privately insured population (Brown et al., 2005) . Finally, because the study is limited to patients with ADHD during relatively long periods of stimulant treatment, the results do not apply to patients who are managed either without stimulants or with short stimulant trials.
The current findings suggest that several patient factors are associated with an increased risk of injury in the community treatment of ADHD, including adolescence age, male gender, comorbid mood disorder, and treatment with an anxiolytic or hypnotic medication. Clinicians treating patients with these characteristics should be especially vigilant in their efforts to help protect them from injury. Further research is needed to determine whether and under what clinical conditions stimulant treatment helps protect patients from the risk of injuries.
